

## AllerGenis to Present at the 38th Annual J.P. Morgan Healthcare Conference

*Presentation to take place at 10:15 a.m. PT on January 14*

**HATFIELD, Penn. – January 8, 2020** – AllerGenis, a data-driven precision diagnostics company focused on food allergies, today announced that CEO Jim Garner will be presenting during the Biotech Showcase at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Mr. Garner’s presentation will highlight the upcoming 2020 introduction of AllerGenis’ food allergy diagnostic platform, which more than triples diagnostic precision compared to current food allergy testing.

Presentation Title: Revolutionizing the Diagnosis and Management of Food Allergy

Date & Time: Tuesday, January 14, 10:15 a.m. PT (1:15 p.m. ET)

Location: Hilton San Francisco Union Square

Track: Franciscan D (Ballroom Level)

The presentation can be webcast live ([Link](#)), and will be available for streaming on the “Resources” section of the company’s website, [www.allergen.com](http://www.allergen.com), following the presentation.

With the prevalence increasing and annual costs of food allergies reaching \$25 billion, accurate diagnostics can ensure food allergic patients receive proper care. Yet, through a combination of over testing, misinterpretation of results and lack of sophistication in current tools, as many as 60 percent of patients are overdiagnosed with food allergies. AllerGenis’ new diagnostic platform, which has been validated to have a 95% concordance with oral food challenge, the current gold standard, will help healthcare providers remedy food allergy overdiagnosis.

### About AllerGenis

AllerGenis develops precision, data-driven diagnostics, which enable healthcare providers to more accurately and safely diagnose, assess and monitor patients with food allergies. AllerGenis was formed through a research collaboration with Hugh Sampson, MD, Director of the Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai. This led to the development of next-generation epitope mapping diagnostic technology, which subdivides allergenic proteins into smaller peptides to measure allergies at the molecular level, in a multiplexed manner. The platform represents the first precision diagnostic solution in food allergy management: with means to identify, diagnose, calibrate and manage a patient, with sensitivity and specificity far greater than any currently available test methods. AllerGenis is also creating the largest food allergy knowledge base of individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain greater clinical insights.

#### Media Contact

Azeem Zeekrya

312-506-5244

[azeem.zeekrya@hdmz.com](mailto:azeem.zeekrya@hdmz.com)

#### Investment contact

Russ Fein

646-572-0421

[russ@corporatefuel.com](mailto:russ@corporatefuel.com)